TELCON RF PHARMACEUTICAL. Statistics

Total Valuation

TELCON RF PHARMACEUTICAL. has a market cap or net worth of KRW 66.98 billion. The enterprise value is 100.32 billion.

Market Cap	66.98B
Enterprise Value	100.32B

Important Dates

The last earnings date was Monday, November 11, 2024.

Earnings Date	Nov 11, 2024
Ex-Dividend Date	n/a

Share Statistics

TELCON RF PHARMACEUTICAL. has 120.25 million shares outstanding. The number of shares has decreased by -24.99% in one year.

Current Share Class	n/a
Shares Outstanding	120.25M
Shares Change (YoY)	-24.99%
Shares Change (QoQ)	+0.62%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.47%
Float	91.88M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.65
PB Ratio	0.73
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.33
EV / Sales	2.60
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-49.92

Financial Position

The company has a current ratio of 0.34, with a Debt / Equity ratio of 0.43.

Current Ratio	0.34
Quick Ratio	0.19
Debt / Equity	0.43
Debt / EBITDA	8.54
Debt / FCF	-19.88
Interest Coverage	0.24

Financial Efficiency

Return on equity (ROE) is -23.18% and return on invested capital (ROIC) is 0.16%.

Return on Equity (ROE)	-23.18%
Return on Assets (ROA)	0.15%
Return on Capital (ROIC)	0.16%
Revenue Per Employee	309.08M
Profits Per Employee	-185.49M
Employee Count	125
Asset Turnover	0.27
Inventory Turnover	5.30

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -51.99% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-51.99%
50-Day Moving Average	591.24
200-Day Moving Average	711.12
Relative Strength Index (RSI)	36.20
Average Volume (20 Days)	600,629

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TELCON RF PHARMACEUTICAL. had revenue of KRW 38.63 billion and -23.19 billion in losses. Loss per share was -202.64.

Revenue	38.63B
Gross Profit	10.29B
Operating Income	335.65M
Pretax Income	-23.23B
Net Income	-23.19B
EBITDA	4.68B
EBIT	335.65M
Loss Per Share	-202.64

Full Income Statement

Balance Sheet

The company has 6.91 billion in cash and 39.95 billion in debt, giving a net cash position of -33.04 billion or -274.75 per share.

Cash & Cash Equivalents	6.91B
Total Debt	39.95B
Net Cash	-33.04B
Net Cash Per Share	-274.75
Equity (Book Value)	92.42B
Book Value Per Share	766.07
Working Capital	-36.46B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.78 billion and capital expenditures -4.79 billion, giving a free cash flow of -2.01 billion.

Operating Cash Flow	2.78B
Capital Expenditures	-4.79B
Free Cash Flow	-2.01B
FCF Per Share	-16.71

Full Cash Flow Statement

Margins

Gross margin is 26.64%, with operating and profit margins of 0.87% and -60.01%.

Gross Margin	26.64%
Operating Margin	0.87%
Pretax Margin	-60.14%
Profit Margin	-60.01%
EBITDA Margin	12.10%
EBIT Margin	0.87%
FCF Margin	-5.20%

Dividends & Yields

TELCON RF PHARMACEUTICAL. does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	24.99%
Shareholder Yield	24.99%
Earnings Yield	-36.38%
FCF Yield	-3.00%

Stock Splits

The last stock split was on August 12, 2016. It was a forward split with a ratio of 5.

Last Split Date	Aug 12, 2016
Split Type	Forward
Split Ratio	5

Scores

TELCON RF PHARMACEUTICAL. has an Altman Z-Score of -0.61. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.61
Piotroski F-Score	n/a